- Home
- ELOG vs BCAB Comparison
ELOG vs BCAB Comparison
Compare ELOG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELOG | BCAB |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 20.8M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ELOG | BCAB |
|---|---|---|
| Price | $1.08 | $0.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 121.8K | ★ 3.1M |
| Earning Date | 02-27-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.27 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $45,962,309.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | ★ 10.64 | N/A |
| 52 Week Low | $0.85 | $0.14 |
| 52 Week High | $3.60 | $1.43 |
Technical Indicators
Market Signals| Indicator | ELOG | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.24 | 27.47 |
| Support Level | $0.85 | $0.15 |
| Resistance Level | $1.13 | $0.21 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 43.60 | 7.74 |
Price Performance
Historical ComparisonAbout ELOG Eastern International Ltd. Ordinary Shares
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.